Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 6/20 | 0.36 |
| ▸ | HTR3A | P46098 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052062 | 0.89 | HTR6 (0.42) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31052182 | 0.80 | ADRB1 (0.61) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31052145 | 0.79 | ADRB1 (0.59) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31052009 | 0.74 | DRD2 (0.47) | ADRB1HTR1AHTR3A | |
| SCHEMBL31051722 | 0.74 | DRD2 (0.43) | ADRB1HTR1AHTR3A | |
| SCHEMBL31051787 | 0.73 | ADRB1 (0.38) | ADRB1HTR1AHTR3A | |
| SCHEMBL31051920 | 0.71 | ADRB1 (0.61) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31051841 | 0.70 | HTR6 (0.41) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31052237 | 0.70 | ADRB1 (0.41) | HTR6ADRB1HTR1AHTR3A | |
| SCHEMBL31052101 | 0.70 | HTR6 (0.38) | HTR6ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |